anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Application of DDIT3 as a breast cancer drug resistance detection target relates to the technical field of biological engineering, in particular to application of DDIT3 as a breast cancer drug resistance detection target. The drug is used for solving the problem that the existing luminal A breast cancer patient has drug resistance to tamoxifen. In the invention, the expression difference of DDIT3 is found to be the most obvious in the TAM drug-resistant luminal A breast cancer MCF7 cell line. Finally, after DDIT3 is silenced, the cell proliferation speed is obviously improved, and the cell drug resistance is obviously improved. DDIR3 can be used as a molecular marker for diagnosing sensitivity and drug resistance of human luminal A breast cancer 4-OHT. Sensitivity and resistance of the luminal a breast cancer patient to TAM can be distinguished by measuring the expression level of DDIT 3.
FIELD: medicine, virology. SUBSTANCE: polyprenylphosphate of the general formula   is proposed. This compound is used as antiviral agent, which shows activity in vitro against human immunodeficiency virus, hepatitis A virus and in vivo against tick-borne encephalitis, carnivores plague, ectromelia, viral gastroenteritis, etc. Early polyprenylphosphate and its analogues are used as hypotensive and antiulcerous drugs, hepatoprotectors and agents, which are able to restore sensitivity of tumor cells to cytostatics. EFFECT: enhanced efficacy of agent. 3 tbl
Participants will take ketoprofen for six months. They will have evaluations at baseline and month 6.
INTRODUCTION: The key outcome of joint registries is revision events, which inform clinical practice and identify poor-performing implants. Registries record revision events and reasons, but accuracy may be limited by a lack of standardized definitions of revision. Our study aims to assess the accuracy and completeness of unicompartmental knee arthroplasty (UKA) revision and indications reported to the New Zealand Joint Registry (NZJR) with independent clinical review.
METHODS: Case record review of 2272 patients undergoing primary UKA at four large tertiary hospitals between 2000 and 2017 was performed, identifying 158 patients who underwent revision. Detailed review of clinical findings, radiographs and operative data was performed to identify revision cases and the reasons for revision using a standardized protocol. These were compared to NZJR data using chi-squared and Fisher exact tests.
RESULTS: The NZJR recorded 150 (95%) of all UKA revisions. Osteoarthritis progression was the most common reason on the systematic clinical review (35%), however, this was underreported to the registry (8%, P < 0.001). A larger proportion of revisions reported to the registry were for 'pain' (30% of cases vs. 5% on clinical review, P < 0.001). A reason for revision was not reported to the registry for 10% of cases.
CONCLUSION: The NZJR had good capture of UKA revisions, but had significant differences in registry-reported revision reasons compared to our independent systematic clinical review. These included over-reporting of 'pain', under-reporting of osteoarthritis progression, and failing to identify a revision reason. Efforts to improve registry capture of revision reasons for UKA could be addressed through more standardized definitions of revision and tailored revision options for UKA on registry forms.
This is a multi-centre observational prospective study that was planned for assessment the effectiveness of neurotropic vitamins therapy with Milgamma®/ Milgamma® compositum in combination with modern NSAIDs (preferential/selective cyclooxygenase-2 (COX-2) inhibitors) in patients with acute non-specific back pain. Approximately 500 adult out-patients with acute non-specific low back pain who have been prescribed therapy consisting of (1) modern NSAIDs (preferential/selective COX-2 inhibitors) or (2) modern NSAIDs (preferential/selective COX-2 inhibitors) + Milgamma® / Milgamma® compositum will be enrolled in the study. Each patient will be observed over a period of approximately 94 days. 9 visits/phone contacts are planned to be conducted during this period. Information about patient's condition, pain intensity, pain flare-ups, satisfaction with the treatment, patient's disability, therapy used for acute back pain treatment, data on safety will be collected during these contacts. Pain intensity will be measured with Numeric Rating Scale (NRS), patients' disability will be evaluated with Roland Morris disability questionnaire, patients' satisfaction with the treatment will be assessed with 5-point verbal rating scale. Safety assessment will be based on frequency and severity of adverse drug reactions recorded during the study.

Prior to the start of the study, neurologists (potential investigators) will be asked to fill out feasibility questionnaires to identify their individual routine practice regarding prescription or non-prescription of Milgamma® / Milgamma® compositum. Based on results of feasibility physicians will be divided to non-prescribers and prescribers of Milgamma® / Milgamma® compositum to the patients with acute non-specific low back pain. In each medical institution, such non-prescribers and prescribers will be proposed to participate in the study. Non-prescribers will be responsible for enrolling group (1) (NSAIDs alone), prescribers will be responsible for enrolling group (2) (NSAIDs + Milgamma® / Milgamma® compositum).
A method for performing a patient oxygenation test using one or more computing devices is provided. The patient oxygenation test comprises a plurality of instructions for implementing a workflow for determining an oxygenation status for a patient. An entry or selection is received of one or more physiological parameters for the patient to be monitored during the patient oxygenation test. An entry or selection is received of one or more thresholds for at least one of the physiological parameters to be monitored during the patient oxygenation test. A determination is made as to whether any of the physiological parameters exceed limits set by the one or more thresholds. One or more actions are taken when one or more of the physiological parameters exceed the limits set by the one or more thresholds. A summary and analysis are provided of the test results.
The study recruited 60 patients with Acrophobia and randomly assigned them to the VR treatment group and the imaginary exposure treatment group. Recruitment conditions for Acrophobia: The Acrophobia questionnaire scored more than 45.45 points; Age 18-55 years old; Right-handedness; No psychotherapy or psychiatric medication for six months; Normal vision or corrective vision; Not during pregnancy or lactation. Before the formal treatment, the participants were interviewed, mainly to understand in detail the fear of heights in the subjects, and to tell the subjects the reasons for the fear of heights and the principles of our treatment. After confirming the participants 'intention to participate in the treatment, a heart test was conducted to eliminate heart problems and finally sign an informed consent form. At the end of the interview, pre-tests were performed to collect fear of heights questionnaires, high attitude questionnaires, behavioral avoidance tests, and nuclear magnetic data collection. There were a total of 5 treatments in the VR treatment group, followed by cliffs, cliffs, cliffs, single-plank bridges, and high-altitude rescues. The difficulty of the scene increased in turn. The frequency of treatment twice a week, about 30 minutes each time, fills in the motion sickness questionnaire before and after each treatment to understand the safety of VR treatment. In the course of treatment, physiological data such as skin electricity, skin temperature, heart rate, and blood volume were measured, and the state of the subjects was objectively evaluated. At the same time, every two minutes, participants were asked about sud values and recorded. Visualizing exposure therapy is to achieve the goal of exposure by transforming the five scenes of VR exposure therapy through language and guiding the subjects through the guidance language. Both treatment groups were required to collect scales and nuclear magnetic data before, after and after six months of follow-up. In addition, at the beginning of this treatment program, an experimental study was added to understand the characteristics of eye movement in people with anorexia. By looking at high altitude images, recording their eye movement characteristics and physiological feedback, and rating the anxiety levels of each image, adding to the normal control group, we found a high altitude image that can cause high altitude fear in people with high altitude fear. And lay the foundation for future related research.
Part B will consist of a single 400 mg dose of an immediate release capsule of CTP-499 administered under fasting conditions. In Part B 6 subjects will be enrolled.
The primary components of the intervention included: "Get-to-know-you" sessions aimed specifically at providing youth guided social opportunities to foster friendships, group belonging, and social skills, and novel socially-oriented 'PA sessions' infused within the daily time slot that ASPs' allocated towards recreation. Drawing from theoretical models of motivation, and the investigators' previous ASP studies, key essential elements were identified for facilitating improvements in targeted PA social mechanisms (i.e., friendships, group belonging, and staff connection) and included: 1) social-emotional goal-oriented support, 2) collaborative/cooperative play centered on friendship and informal fun; 3) equal treatment/access, and; 4) inclusive and engaging.
Age, weight, and severity of the infection are important factors in determining the proper dosage. The usual dosage is 30 to 50 mg/kg/day, in equally divided doses. For more severe infections, this dose may be doubled but should not exceed 4 g per day.

In the treatment of streptococcal infections of the upper respiratory tract (e.g., tonsillitis or pharyngitis), the therapeutic dosage of erythromycin should be administered for at least ten days.

The American Heart Association suggests a dosage of 250 mg of erythromycin orally, twice a day in long-term prophylaxis of streptococcal upper respiratory tract infections for the prevention of recurring attacks of rheumatic fever in patients allergic to penicillin and sulfonamides. 1
BACKGROUND: Ischemic stroke (IS) is a cerebrovascular disease caused by various factors, and its etiology remains inadequately understood. The role of immune system dysfunction in IS has been increasingly recognized. Our objective was to evaluate whether circulating immune cells causally impact IS risk.
METHODS: We conducted two-sample Mendelian randomization analyses to evaluate the causal effects of 731 immune cell traits on IS, utilizing publicly available genome-wide association studies (GWAS) summary statistics for 731 immune cell traits as exposure data, and two GWAS statistics for IS as outcome data. A set of sensitivity analyses, including Cochran's Q test, I 2 statistics, MR-Egger intercept test, MR-PRESSO global test, and leave-one-out sensitivity analyses, were performed to assess the robustness of the results. Additionally, meta-analyses were conducted to combine the results from the two different IS datasets. Finally, we extracted instrumental variables of immune cell traits with causal effects on IS in both IS datasets for SNP annotation.
RESULTS: A total of 41 and 35 immune cell traits were identified to have significant causal effects on IS based on two different IS datasets, respectively. Among them, the immune cell trait CD62L- plasmacytoid Dendritic Cell AC and CD4+ CD8dim T cell%leukocyte respectively served as risk factor and protective element in both IS datasets. The robustness of the causal effects was confirmed through the sensitivity analyses. The results of the meta-analyses further support the causal effects of CD62L- plasmacytoid Dendritic Cell AC (pooled OR=1.030, 95%CI: 1.011-1.049, P=0.002) and CD4+ CD8dim T cell%leukocyte (pooled OR=0.959, 95%CI: 0.935-0.984, P=0.001). Based on these two immune cell traits, 33 genes that may be related to the causal effects were mapped.
CONCLUSIONS: Our study demonstrated the potential causal effects of circulating immune cells on IS, providing valuable insights for future studies aimed at preventing IS.
ABSTRACT - 595196 Peptide-based compounds of formula (I) which include heteroatom-containing, three membered rings are disclosed, wherein the variables are as defined in the specification. These compounds efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. These peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, these peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profiles. These compounds are particularly suitable for treating septic shock, parasitic infections, conditions associated with acidosis, pulmonary conditions, nerve injury, hepatic failure, ischemic condition or reperfusion injury selected from the group consisting of: acute coronary syndrome, arterial occlusive disease, atherosclerosis, infarctions, heart failure, pancreatitis, myocardial hypertrophy, stenosis, and restenosis, and for the inhibition of cell adhesion.
Protection from heat, air and U.V. light is afforded to soaps by compounds of the general formula <FORM:1061521/C4-C5/1> where R is a phenyl radical, bound to the ring via a cyclic carbon atom, containing a hydroxyl group ortho to the ring bond, and a group -OW, where W is alkenyl or substituted alkyl, and A and X are substituted or unsubstituted phenyl radicals bound to the ring via a cyclic carbon atom.ALSO:The invention comprises compounds of the formula <FORM:1061521/C2/1> where R is a phenyl radical bound through a cyclic carbon atom to the ring and containing a hydroxyl group ortho to the triazine ring bond, and a group -OW, where W is alkenyl or substituted alkyl, and A and X are substituted or unsubstituted phenyl radicals bound through a cyclic carbon atom to the ring.  They are obtained by reacting in an anhydrous medium in the presence of a Friedel Crafts catalyst and an inert organic solvent, a halogeno-1: 3: 5-triazine with a compound of the benzene series containing two hydroxyl groups in meta-position to each other, and optionally with other compounds of the benzene series, whereupon the resulting hydroxylated product is reacted with a suitable etherifying agent. Examples of substituted alkyl groups are hydroxyalkyl, hydroxyalkoxyalkyl, halogenoalkyl, cyanoalkyl, carboxyalkyl, carbalkoxyalkyl, aralkyl and acyalkyl.  Examples of alkenyl groups are vinyl, allyl and crotyl.  Suitable etherifying agents are ethylenechlorohydrin, glycerin-a -chlorohydrin, n-allylbromide, benzyl-chloride, para-chlorobenzyl chloride, crotyl bromide, g -bromobutyronitrile, g -bromobutyric acid ethyl ester, 1-chloro-3-bromopropane, phenacyl bromide, chloracetic acid ethyl ester, chloroacetic acid and bromoacetic acid glycol ester.ALSO:Protection from heat, air and UV light is afforded to fibrous materials which may be in the form of yarns, woven or knitted fabrics, felt, textiles and papers, for example those based on starch or casein or on synthetic resins, by compounds of the general formula:  <FORM:1061521/D1-D2/1> where R is phenyl radical, bound to the ring via a cyclic carbon atom, containing a hydroxyl group ortho to the ring bond, and a group -OW where W is alkenyl or substituted alkyl and A and X are substituted or unsubstituted phenyl radicals bound to the ring via a cyclic carbon atom.ALSO:Protection from heat, air and VV light is afforded to cosmetic preparations such a perfumes, bath salts, skin and face creams, powders, repellants and sunburn oils and creams by compounds of the formula <FORM:1061521/A5-A6/1> where R is a phenyl radical bound to the ring via a cyclic carbon atom, containing a hydroxyl group ortho to the ring bond, and a group -OW where W is alkenyl or substituted alkyl, and A and X are substitued or unsubstituted phenyl radicals bound to the ring via a cyclic carbon atom.
1. Mineralized drinking water comprising water, water-soluble calcium, magnesium and fluorine compounds, characterized in that comprises by at least one non-organic compound of calcium, magnesium and fluorine, the concentration of which based on calcium, magnesium and fluorine is correspondingly 0.05-200 mg/liter; 0.1-140 mg/liter and 0.05-1.5 mg/liter and bicarbonates in the concentration of 30-400 mg/liter, wherein natural water, natural low-mineralized water or natural partially or fully-desalted water. 2. The water of claim 1, characterized in that it may further contain water-soluble iodine compound in the form of its organic or non-organic compound in concentration of 30-200 micg/liter. 3. The water of any of claims 1-2, characterized in that it may further contain at least one organic selenium compound the concentration of which is 1-20 micg/liter based on selenium. 4. The water of any of claims 1-3, characterized in that it may further contain non-organic potassium compounds the concentration of which is 1.5-40 mg/liter based on potassium. 5. The water of any of claims 1-3, characterized in that it may further contain silver ions added mainly electrolytically to their final concentration of 5-50 micg/liter. 6. The water of claim 1, characterized in that the concentration of calcium is 60-80 mg/liter, magnesium 12-40 mg/liter, fluorine 0.6-1.2 mg/liter, potassium 15-25 mg/liter and bicarbonates 30-200 mg/liter. 7. The water of claim 6, characterized in that it may further contain organic or non-organic iodine compound in concentration of 30-100 micg/liter. 8. The water of any of claims 6-7, characterized in that it may further contain an organic selenium compound the concentration of which is 5-10 micg/liter. 9. The water of any of claims 6-8, characterized in that it may further contain sodium the concentration of which is equal or at least 5-10 micg/liter. 10. The water of any of claims 6-8, characterized in that the water is used for preparing beverages or food products preliminary subjected to thermal, laser, high or low-frequency magnetic, cold plasma, electrochemical, and other energy information treatment. 11. The water of claim 10, characterized in that it further contains dissolved oxygen or carbon dioxide.
At randomization, subjects will receive one matching placebo capsule twice per day for one week. They will also take one matching placebo capsule twice per day for the next week (week 2), then one matching placebo capsule in the morning and two capsules at night for one week (week three), and finally two capsules twice per day for three weeks (weeks 4-6). Maximum tolerated number of capsules will be determined at this time and this dose will be continued for an additional six weeks.
This is a study from the real world. Advanced refractory solid tumors patients with no standard treatment options have a very poor prognosis. In recent years, the application of s Next Generation Sequencing (NGS) has rapidly expanded the breadth and depth of understanding of the molecular mechanism of tumors, laying a foundation for the development of precision medicine for tumors. Researchers can build a molecular phenotype of advanced refractory solid tumors by NGS. Some retrospective study shows that Molecular Tumor Board (MTB) therapy model brings therapeutic hope. So, investigators hope that this therapy model combined with NGS may provide treatment recommendations for advanced refractory solid tumors patients. Those recommendations may include some off-label targeted therapies. This study seeks to evaluate the clinical value of the personalized therapy model with the guidance of MTB after NGS, and to track patient outcomes, including ORR (Objective Response Rate), PFS (Progression Free Survival), OS (Overall Survival) and ADR (Adverse Drug Reaction).
Participant will receive macitentan at a dose of 10 milligram (mg) once daily (OD) for 4 weeks, followed by a dose of macitentan 37.5 mg for another 4 weeks and continue with the target dose of macitentan 75 mg. Participants who have reached the target dose of 75 mg, completed the Double-blind (DB) period up to Week 28 (either on treatment or in Post-treatment observation period \[PTOP\]) at minimum, may be eligible for transitioning into the Open label (OL) extension period once all participants have completed the DB part of the study, or earlier if they experienced a Clinical event committee (CEC) confirmed clinical worsening event.
This case series evaluated use of injectable platelet rich fibrin (termed i-PRF+) for the treatment of female pattern hair loss (FPHL). Eleven individuals underwent 3-monthly intradermal injections of i-PRF+ using a mesotherapy gun. The mean number of hair follicles containing hairs per unit area improved at 3- and 6-months follow-up (p < .001), and all participants had a negative hair pull test. Hair volume and thickness, and patient-reported outcome scores also improved at follow-up (p < .001). Adverse effects were minor and self-limited. A series of three i-PRF+ injection sessions were effective for the treatment of FPHL, as shown by improved hair analysis parameters and patient self-assessment scores.
Intubation for mechanical ventilation (MV) is one of the most common high-risk procedures performed in Intensive Care Units (ICUs). Early prediction of intubation may have a positive impact by providing timely alerts to clinicians and consequently avoiding high-risk late intubations. In this work, we propose a new machine learning method to predict the time to intubation during the first five days of ICU admission, based on the concept of cure survival models. Our approach combines classification and survival analysis, to effectively accommodate the fraction of patients not at risk of intubation, and provide a better estimate of time to intubation, for patients at risk. We tested our approach and compared it to other predictive models on a dataset collected from a secondary care hospital (AZ Groeninge, Kortrijk, Belgium) from 2015 to 2021, consisting of 3425 ICU stays. Furthermore, we utilised SHAP for feature importance analysis, extracting key insights into the relative significance of variables such as vital signs, blood gases, and patient characteristics in predicting intubation in ICU settings. The results corroborate that our approach improves the prediction of time to intubation in critically ill patients, by using routinely collected data within the first hours of admission in the ICU. Early warning of the need for intubation may be used to help clinicians predict the risk of intubation and rank patients according to their expected time to intubation.
Signs and symptoms of overdosage may be immediate, such as nausea, vomiting, malaise, hypotension, and diaphoresis; or delayed, such as myelosuppression and azotemia. It is not known whether thioguanine is dialyzable. Hemodialysis is thought to be of marginal use due to the rapid intracellular incorporation of thioguanine into active metabolites with long persistence. The oral LD50 of thioguanine was determined to be 823 mg/kg ± 50.73 mg/kg and 740 mg/kg ± 45.24 mg/kg for male and female rats, respectively. Symptoms of overdosage may occur after a single dose of as little as 2.0 to 3.0 mg/kg thioguanine. As much as 35 mg/kg has been given in a single oral dose with reversible myelosuppression observed. There is no known pharmacologic antagonist of thioguanine. The drug should be discontinued immediately if unintended toxicity occurs during treatment. Severe hematologic toxicity may require supportive therapy with platelet transfusions for bleeding, and granulocyte transfusions and antibiotics if sepsis is documented. If a patient is seen immediately following an accidental overdosage of the drug, it may be useful to induce emesis.